The University of Southampton
University of Southampton Institutional Repository

Therapeutic potential of immunostimulatory monoclonal antibodies

Therapeutic potential of immunostimulatory monoclonal antibodies
Therapeutic potential of immunostimulatory monoclonal antibodies
The aim of cancer immunotherapy is to employ the specificity of the immune system to provide a more effective, less toxic, treatment compared with conventional therapies. Although many strategies have been used to try to generate effective anticancer immune responses, very few have reached mainstream clinical use. A new approach introduced over the last few years is to use immunostimulatory mAbs (monoclonal antibodies) to boost weak endogenous antitumour immune responses to levels which are therapeutic. Such agonistic or antagonistic mAbs bind to key receptors in the immune system acting to enhance antigen presentation, provide co-stimulation or to counteract immunoregulation. In animal models, this approach has been shown to promote powerful tumour-specific T-cell responses capable of clearing established tumour and leaving the animal with long-term immunity. In addition to this impressive therapy seen in tumour models, these same mAbs also have the potential to be therapeutically useful in autoimmune and infectious diseases. This review discusses the use of these mAbs as therapeutic agents, their advantages and disadvantages and the challenges that need to be overcome to use them clinically
dendritic cells, immune-responses, clonal expansion, antitumor immunity, antigen presentation, autoimmune-disease, models, monoclonal antibody, immunotherapy, immunity, monoclonal-antibodies, 4-1bb ligand, cancer, costimulatory molecule, costimulation, inummostimulatory, disease, in-vivo, antigen, responses, model, regulatory t-cells, immune response, antitumour therapy, time, metastatic melanoma, t-cell
0143-5221
93-106
Gray, J.C.
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Johnson, P.W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Glennie, M.J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Gray, J.C.
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Johnson, P.W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Glennie, M.J.
9f6f0eff-4560-48c2-80cd-0ec116110ded

Gray, J.C., Johnson, P.W.M. and Glennie, M.J. (2006) Therapeutic potential of immunostimulatory monoclonal antibodies. Clinical Science, 111 (2), 93-106.

Record type: Article

Abstract

The aim of cancer immunotherapy is to employ the specificity of the immune system to provide a more effective, less toxic, treatment compared with conventional therapies. Although many strategies have been used to try to generate effective anticancer immune responses, very few have reached mainstream clinical use. A new approach introduced over the last few years is to use immunostimulatory mAbs (monoclonal antibodies) to boost weak endogenous antitumour immune responses to levels which are therapeutic. Such agonistic or antagonistic mAbs bind to key receptors in the immune system acting to enhance antigen presentation, provide co-stimulation or to counteract immunoregulation. In animal models, this approach has been shown to promote powerful tumour-specific T-cell responses capable of clearing established tumour and leaving the animal with long-term immunity. In addition to this impressive therapy seen in tumour models, these same mAbs also have the potential to be therapeutically useful in autoimmune and infectious diseases. This review discusses the use of these mAbs as therapeutic agents, their advantages and disadvantages and the challenges that need to be overcome to use them clinically

Full text not available from this repository.

More information

Published date: 2006
Keywords: dendritic cells, immune-responses, clonal expansion, antitumor immunity, antigen presentation, autoimmune-disease, models, monoclonal antibody, immunotherapy, immunity, monoclonal-antibodies, 4-1bb ligand, cancer, costimulatory molecule, costimulation, inummostimulatory, disease, in-vivo, antigen, responses, model, regulatory t-cells, immune response, antitumour therapy, time, metastatic melanoma, t-cell

Identifiers

Local EPrints ID: 62759
URI: http://eprints.soton.ac.uk/id/eprint/62759
ISSN: 0143-5221
PURE UUID: 7fedd461-52d6-4bbd-9077-ad254b208151
ORCID for P.W.M. Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 10 Sep 2008
Last modified: 10 Dec 2019 01:51

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×